Fig. 5: Characterization of TNKS1/2 pathway in ALK1510-c4 cells and ALK1510-c4 DTP cells. | npj Precision Oncology

Fig. 5: Characterization of TNKS1/2 pathway in ALK1510-c4 cells and ALK1510-c4 DTP cells.

From: Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer

Fig. 5

a The relative mRNA expression of TNKS1 and TNKS2 (TNKS1/2) in ALK1510-c4 cells and ALK1510-c4 DTP cells determined by RT-PCR (using the TaqMan probes) was calculated as the ratio of the normalized value (with GAPDH mRNA expression) (mean [SD] of n = 3 experiments; *P < 0.05 versus ALK1510-c4 cells; Dunnett’s test). b Immunoblots of cell lysates evaluating Wnt/β-catenin signaling in ALK1510-c4 cells treated with 1000 nM alectinib for 1, 3, 24, and 48 h and 9 days. c Immunoblots of cytosolic or nuclear lysates from ALK1510-c4 cells treated with 1000 nM alectinib for 24 h and 9 days.

Back to article page